---
title: miRdetect
date: 2019-03-29T08:56:23Z
modified: 2026-08-13T11:35:38Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/mirdetect/"
type: portfolio
status: publish
excerpt: ""
wpid: 70854
language:
  - English
post_translations:
  - pll_5c9ddcf4a5c19
branchen22:
  - In-Vitro Dx
sectors:
  - Diagnostics & R&D Tools
focus_areas:
  - Diagnostics
  - Oncology
timestamp: 2026-08-13T11:35:38Z
tags:
  - English
  - pll_5c9ddcf4a5c19
  - In-Vitro Dx
  - Diagnostics & R&D Tools
  - Diagnostics
  - Oncology
---

## Beschreibungstext

miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic methods. The first product, based on the quantification of microRNA, is a blood test for the detection of testicular cancer. The high sensitivity and accuracy of the test improves the diagnosis and therapy of patients significantly and reduces the costs for the health care system. miRdetect has developed a patented platform technology, which allows the exact and reliable quantification of small amounts of genetic material in body fluids. This robust method represents the basis for the development of additional diagnostic tests.

## Unternehmenswebsite

> [Hochleistungs-Tumor-Tests](https://www.mirdetect.de/)

## Adresse

Fahrenheitstraße 1
 28359 Bremen

## Kontakt

Array

Array